RBC Platform Advantage Functional Fluidics offers a unique RBC health platform built on two proprietary tests—the mechanical fragility index and the adhesion index—that quantify red cell resilience and stickiness; this differentiated diagnostic capability creates direct sales opportunities with hospitals, blood banks, and transfusion medicine labs seeking objective RBC health metrics to guide patient care and transfusion decisions.

Strategic Partnership Potential The investment from NYBC Ventures validates interest from major blood center ecosystems and opens doors for collaborative R&D in sickle cell disease and transfusion medicine, presenting co-selling or joint-development opportunities with blood centers and associated research institutions.

Broad Testing Portfolio Beyond RBC health, Functional Fluidics provides Covid-19 tests and antibody testing for workplaces, schools, and colleges, creating cross-sell opportunities to existing healthcare buyers and organizations requiring ongoing testing programs.

Mid-market Focus With a mid-sized team and growing revenue, the company is well positioned to target mid-market hospital systems, community clinics, and blood banks through pilots and scalable service agreements.

Data Driven Marketing A marketing and sales tech stack featuring HubSpot Analytics and Google Analytics supports data-driven outreach to healthcare buyers, enabling targeted campaigns, demand generation, and measurable ROI as the company scales.